Key Points {#FPar1}
==========

Paracetamol is widely used for analgesia in osteoarthritis despite reported low efficacy, with use largely driven by a lack of effective or tolerated alternative treatments, and its relative safety.However, there is some evidence demonstrating gastrointestinal, cardiovascular, hepatic and renal toxicity with paracetamol, perhaps reflecting populations that use this drug, but requiring further investigation.Although paracetamol remains safer than some alternative therapies, such as non-steroidal anti-inflammatory drugs, paracetamol should be used carefully, particularly for chronic pain management.

Introduction {#Sec1}
============

Osteoarthritis (OA) is a major cause of pain in adults \[[@CR1]\]. Pain associated with OA of the hip and knee results in increased physical and walking disability, which increases the risk of all-cause mortality \[[@CR2]\]. OA is an increasingly common disease given its associations with aging and a growing obese/overweight population, with symptomatic knee OA affecting more than 250 million older people (\>50 years) worldwide \[[@CR3]\]. Paracetamol (acetaminophen), discovered over 140 years ago, is still one of the most commonly used analgesic and antipyretic medications across the world, and is included on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system \[[@CR4], [@CR5]\]. The management of pain in OA is based on a combination of pharmacologic and non-pharmacologic approaches, with paracetamol commonly recommended for analgesia at an early step in treatment recommendations \[[@CR6]--[@CR9]\]. Use is often driven by an absence of therapeutic alternatives, especially given the safety profile of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Each year in the US, approximately 6% of adults are prescribed paracetamol doses of more than 4 g/day, and 30,000 patients are hospitalized for paracetamol toxicity \[[@CR10]\]. Although traditionally considered safe, in recent years, a steady increase in the number of registered cases of paracetamol-induced liver toxicity has been observed worldwide \[[@CR4]\]. Although older patients are among the highest users of analgesic medications for musculoskeletal pain, there is limited clinical evidence to inform on the safe and effective use of these medications in the elderly population \[[@CR11]\]. A review of 83 clinical trials involving \>10,000 subjects treated with simple analgesics found that only 2.3% of people were aged over 65 years \[[@CR12]\]. This narrative literature review aims to describe the use, efficacy and toxicity associated with chronic use of paracetamol for OA pain. Given the paucity of long-term randomized controlled trials (RCTs), safety data from observational, cohort studies were also considered.

The Use of Paracetamol in Osteoarthritis (OA) {#Sec2}
=============================================

Paracetamol is frequently prescribed for analgesia. Among participants in the USA Osteoarthritis Initiative (OAI), over 80% reported using medication for knee pain in the previous 12 months, and 70% had used a conventional analgesic or nutraceutical for more than half of the days of the month, of which paracetamol was taken by 14% of participants \[[@CR13]\]. The 2011 National Health and Wellness Survey (NHWS) collected information on 57,512 adults (aged ≥ 18 years) from the general population of five EU countries. Among people with self-reported peripheral joint OA (*n* = 3750; mostly aged 55--74 years), nearly half (47%) reported prescription medication use, 27% reported use of over-the-counter (OTC) medications, and 9% of patients used both. The prescription of paracetamol was variable, ranging from 0% in Germany up to 6% in Spain, while the use of prescription NSAIDs was highest in Germany (82%) and lowest in France (47%). However, OTC medication use was reported by 15--30% of people \[[@CR14]\], and paracetamol was likely included in this OTC use. Variation in the use of pharmacotherapy for OA between countries may be driven by national prescribing guidelines and health system economics (for example, in countries where costs of medical consultation and prescription outweigh the OTC price for paracetamol, prescription may be low). Of the prescription medications, respondents had been using paracetamol for the longest duration (mean 84 months) and for 21 days of the last month \[[@CR14]\]. A prospective cohort study of analgesic prescribing to older people (aged \> 75 years; *N* = 149) by general practitioners in France found that pain was largely due to OA, and, among those receiving at least one analgesic (66%), almost all received paracetamol (\> 96%), which is in line with national prescribing guidance \[[@CR15]\].

Despite the availability of analgesics, inadequate pain relief is common among patients with knee OA and is associated with large functional loss and impaired quality of life. In an observational study of real-world therapies for OA, after ≥ 2 weeks of physician-prescribed treatment, more than half of patients with knee OA reported inadequate pain relief defined as moderate to severe pain \[[@CR16]\]. The most commonly prescribed analgesic medications were NSAIDs (60% of patients), followed by paracetamol (44%) and opioid-containing medications (27%).

Chronic multiple-site joint pain (MSJP) is common in older people and is associated with poor outcomes. MSJP represents a combination of OA, back pain and soft tissue disorders; muscle weakness is extremely common \[[@CR17]\]. In a cohort of MSJP patients, concurrent pharmacological therapies were used by 47%. Paracetamol was used by 62% of patients (38% on prescription) and 23% regularly used paracetamol. Among the 26% of MSJP patients who had previously stopped taking paracetamol, 98% reported stopping due to inefficacy or a loss of efficacy \[[@CR17]\].

Paracetamol Efficacy in OA {#Sec3}
==========================

Although widely used as a first-line analgesic in OA, there are increasing doubts, from recent meta-analyses, regarding the analgesic efficacy of paracetamol. A Cochrane review on paracetamol in OA, performed over a decade ago, found a significantly superior reduction in pain compared with placebo from seven RCTs, albeit with a small effect size (ES; standardized mean difference \[SMD\] − 0.14, 95% confidence interval \[CI\] − 0.23 to − 0.05) \[[@CR18]\]. In a subsequent analysis adjusting for trial quality, when the five high-quality, placebo-controlled RCTs were considered in isolation (Jadad score = 5), the ES of paracetamol on pain was even smaller (ES 0.10, 95% CI − 0.03 to 0.23) \[[@CR19]\]. This analysis also suggested that paracetamol had no significant effect on stiffness (ES 0.16, 95% CI − 0.05 to 0.37) or physical function (ES 0.09, 95% CI − 0.03 to 0.22) \[[@CR19]\].

In a recent systematic review and meta-analysis, paracetamol was found to provide minimal short-term benefit for people with OA \[[@CR20]\]. For hip or knee OA, there was 'high quality' evidence that paracetamol provided a significant, although not clinically important, effect on pain (weighted mean difference \[WMD\] − 3.7, 95% CI − 5.5 to − 1.9) and disability (WMD − 2.9, 95% CI − 4.9 to − 0.9) in the short term (\> 2 weeks and ≤ 3 months). In the immediate term (≤ 2 weeks), the effect of paracetamol on pain was lower (WMD − 3.3, 95% CI − 5.8 to − 0.8), with no immediate effect on function (WMD − 1.7, 95% CI − 6.0 to 2.6). In a 2017 network meta-analysis of analgesic medications for the management of pain in knee and hip OA, the authors concluded, on the basis of the available data, that there is no role for single-agent paracetamol in the treatment of OA patients irrespective of dose \[[@CR21]\].

A recent meta-analysis focusing on the long-term efficacy of pharmacotherapy for OA \[[@CR22]\], identified only one RCT of \> 12 months' duration that included paracetamol (650 mg, four times daily) in comparison with naproxen (375 mg, twice daily) \[[@CR23]\]. The study found similar efficacy between paracetamol and naproxen among patients who completed the 2-year study (*n* = 27/88 with paracetamol and *n* = 35/90 with naproxen), although a very high withdrawal rate was observed. Withdrawal due to lack of drug efficacy was more frequent for paracetamol (22%) compared with naproxen (16%), with withdrawal due to adverse drug reactions common in both groups, although slightly higher for the NSAID (18% with paracetamol and 23% with naproxen) \[[@CR23]\].

Paracetamol Safety {#Sec4}
==================

Paracetamol is generally considered to be safer than other commonly used analgesics such as NSAIDs or opiates. However, a recent systematic literature review of observational studies (given an absence of long-term trials) reported a considerable degree of toxicity associated with paracetamol use among the general adult population, especially at the upper end of standard analgesic doses \[[@CR24]\]. A striking trend of dose-response was observed between paracetamol at standard analgesic doses and adverse events (AEs) that are often observed with NSAIDs, including an increasing incidence of mortality, cardiovascular, gastrointestinal (GI) and renal AEs in the general population. Eight cohort studies met the inclusion criteria and investigated one or more of the AEs of interest, with oral doses of paracetamol 0.5--1.0 g every 4--6 h to a maximum of 4.0 g/day \[[@CR24]\]. Two of the studies included in this analysis reported on mortality, of which one reported a dose--response increase in all-cause mortality and rate of GI AEs or bleeds based on the low to high medication possession ratio (measured by repeat prescription frequency) (Table [1](#Tab1){ref-type="table"}) \[[@CR25]\]. The other study reported an increase in standardized mortality ratio for patients prescribed paracetamol compared with those not prescribed paracetamol, regardless of the specific cause of death, with a nearly doubled overall death rate \[[@CR26]\]. Four studies included in the meta-analysis showed a dose--response relationship with risk of cardiovascular AEs. One study reported an increasing risk ratio of all cardiovascular AEs based on dosing frequency (Table [1](#Tab1){ref-type="table"}), and three studies included in the meta-analysis reported on the risk of renal AEs with paracetamol, with one study reporting a dose-ranging increase in odds ratio (OR) based on cumulative intake and measured as a ≥ 30% decrease in estimated glomerular filtration rate (eGFR), ranging from 1.80 with up to 500 g in a lifetime (95% CI 1.02--3.18) to 2.04 with \> 3000 g (95% CI 1.28--3.25) \[[@CR27]\].Table 1Increased risk of adverse outcomes with frequent paracetamol dosingAdverse outcomesRepeat use, low MPRRepeat use, medium MPRRepeat use, high MPRRepeat use, very high MPRAll-cause mortality^a^ \[RR (95% CI)\] \[[@CR25]\]0.95 (0.92--0.98)1.08 (1.05--1.11)1.27 (1.21--1.33)1.63 (1.58--1.68)Gastrointestinal AEs^b^ \[RR (95% CI)\] \[[@CR25]\]1.11 (1.04--1.18)1.25 (1.12--1.40)1.49 (1.29--1.72)1.49 (1.34--1.66)PCM 1 day/weekPCM 2--3 days/weekPCM 4--5 days/weekPCM 6--7 days/weekCardiovascular AEs^c^ \[risk ratio (95% CI)\] \[[@CR42]\]0.94 (0.62--1.43)1.23 (0.94--1.61)1.49 (0.99--2.24)1.50 (1.10--2.05)Data compiled from Roberts et al. \[[@CR24]\]*AEs* adverse events, *CI* confidence interval, *IV* instrumental variables, *MPR* medication possession ratio (based on repeat prescription frequency), *PCM* paracetamol, *RR* relative risk^a^The RR (IV, fixed) of all-cause mortality in patients taking paracetamol versus patients not taking paracetamol^b^The RR (IV, fixed) of upper gastrointestinal AEs (gastroduodenal ulcers, and complications such as upper gastrointestinal haemorrhages) in patients taking paracetamol versus patients not taking paracetamol^c^The risk ratio (IV, fixed) of cardiovascular AEs (confirmed or probable non-fatal myocardial infarction, non-fatal stroke, fatal coronary heart disease or fatal stroke) in patients taking paracetamol versus patients not taking paracetamol

Cardiovascular/Cerebrovascular Adverse Events (AEs) {#Sec5}
---------------------------------------------------

### Hypertension {#Sec6}

Concomitant paracetamol can adversely affect the efficacy of antihypertensive therapy (with ramipril or valsartan) \[[@CR28]\]. In a double-blind crossover trial, 174 hypertensive patients with OA were treated with antihypertensives for 8 weeks. Of those patients, 135 with normalized blood pressure were randomized to naproxen or paracetamol for 2 weeks. Naproxen significantly increased clinic and ambulatory systolic/diastolic blood pressure in patients treated with ramipril or valsartan (*p* \< 0.05), but not aliskiren. Paracetamol slightly but significantly affected clinic and ambulatory blood pressure in all three groups and also produced a small but significant increase in heart rate (*p* \< 0.05).

This study cannot account for individual pain over the study period, and pain can drive hypertension. Nevertheless, when paracetamol is chosen for OA management in subjects with hypertension, patients should be evaluated as carefully as when traditional NSAIDs are administered.

### Acute Myocardial Infarction {#Sec7}

The risk of non-fatal acute myocardial infarction (AMI) associated with traditional NSAIDs, non-narcotic analgesics (paracetamol and metamizole), and symptomatic slow-acting drugs in OA (SYSADOAs) was assessed in a Spanish primary care database study of case-control design (cases = 3833, controls = 20,000) \[[@CR29]\]. The greatest risk of non-fatal AMI occurred with high background cardiovascular risk patients and long use of traditional NSAIDs (\> 365 days) (OR 1.80, 95% CI 1.26--2.58). Paracetamol (OR 0.84, 95% CI 0.74--0.95), glucosamine and chondroitin (OR 0.68, 95% CI 0.47--0.99) were not associated with increased risk.

### Stroke {#Sec8}

The risk of non-fatal ischaemic stroke associated with NSAIDs and paracetamol was assessed in a Spanish population-based, case-control study (cases = 2888, controls = 20,000) \[[@CR30]\]. No increased risk was found with paracetamol (OR 0.97, 95% CI 0.85--1.10) or glucosamine and chondroitin (OR 0.94, 95% CI 0.67--1.33), and no increased risk was observed with traditional NSAIDs as a group (OR 1.03, 95% CI 0.90--1.19). Not surprisingly, there was an increased risk with diclofenac (OR 1.53; 95% CI 1.19--1.97), especially with high doses over long-term periods (\>365 days) and in patients with high background cardiovascular risk.

Gastrointestinal (GI) AEs {#Sec9}
-------------------------

In the past, paracetamol was considered to be without GI toxicity, however some studies suggest an increase in GI AE rates with paracetamol use. Two RCTs found the overall rate of GI AEs (most commonly nausea, abdominal pain and dyspepsia) with paracetamol to be similar to that found with ibuprofen, i.e. 9% and 13%, respectively \[[@CR31]\], and 13% and 12%, respectively \[[@CR32], [@CR33]\]. Using patient data from the UK General Practice Research Database (GPRD), an association between paracetamol use and risk of symptomatic ulcer has been found versus non-use (relative risk 1.9, 95% CI 1.5--2.3) \[[@CR34]\]. A nested case-control study from the UK population compared analgesic use in 2105 cases of upper GI bleeding/perforations versus 11,500 age- and sex-matched controls (aged 40--79 years) and found an elevated risk of upper GI complications with paracetamol compared with controls (relative risk \[RR\] 1.3, 95% CI 1.1--1.5), which increased to more than threefold elevated risk among those talking paracetamol at doses \>2 g/day (RR 3.6, 95% CI 2.6--5.1) \[[@CR35]\].

### GI Hospitalization {#Sec10}

The rates of hospitalization for GI disorders (ulceration, perforation, or bleeding in the upper or lower GI tract) among elderly patients (≥ 65 years) taking traditional NSAIDs, or the combination of a traditional NSAID and paracetamol with and without a proton pump inhibitor (PPI) versus those taking paracetamol alone, were assessed among a Canadian population-based retrospective cohort study \[[@CR36]\]. The study found that for elderly patients requiring analgesic/anti-inflammatory treatment, use of the combination of a traditional NSAID and paracetamol may increase the risk of GI bleeding compared with either agent alone. Among the cohort of 644,183 elderly patients, there were 1854 GI hospitalizations. The rate of GI hospitalization was twice as high when an NSAID and paracetamol were used together (with or without a PPI) (Table [2](#Tab2){ref-type="table"}). Patients with OA or rheumatoid arthritis diagnoses (*n* = 115,305, 18% of cohort) had a higher risk of GI events with paracetamol \> 3 g/day compared with the main cohort (hazard ratio \[HR\] 1.42, 95% CI 1.04--1.93).Table 2Rate of gastrointestinal hospitalization among an elderly population-based cohort taking paracetamol, traditional NSAIDs, and PPIsNon-users of PPIsUsers of PPIsDrug exposureUpper/lower GI hospitalizationDrug exposureUpper/lower GI hospitalizationNo. of prescriptionsTotal duration (years)HR (95% CI)No. of prescriptionsTotal duration (years)HR (95% CI)Paracetamol ≤3 g/day2,609,232150,364Reference (1.00)1,032,26958,3440.95 (0.81--1.11)Paracetamol ≥3 g/day1,092,89147,7641.20 (1.03--1.40)504,94323,1881.16 (0.94--1.43)Paracetamol and NSAIDs117,91478582.55 (1.98--3.28)40,80026662.15 (1.35--3.40)NSAIDs1,463,32391,3791.63 (1.44--1.85)315,23819,8391.07 (0.82--1.39)The rates of hospitalization for GI disorders (ulceration, perforation, or bleeding in the upper or lower GI tract) among elderly patients (≥65 years) taking traditional NSAIDs or the combination of a traditional NSAID and paracetamol, with and without a PPI, are compared with the rate for paracetamol alone (≤ 3 g/day) in a Canadian population-based retrospective cohort study (*N* = 644,183)Data compiled from Rahme et al. \[[@CR36]\]*CI* confidence interval, *GI* gastrointestinal, *HR* hazard ratio, *NSAIDs* non-steroidal anti-inflammatory drugs, *PPIs* proton pump inhibitors

Severe Acute Liver Injury {#Sec11}
-------------------------

Paracetamol is a dose-dependent hepatotoxin, and excessive doses may lead to irreversible acute liver failure \[[@CR37]\]. Glucuronidation and sulfation are the major metabolic pathways (phase II) for paracetamol metabolism, which become saturated after paracetamol overdose, causing a shift to phase I metabolism and formation of a toxic metabolite that depletes glutathione and triggers mitochondrial dysfunction, resulting in cellular necrosis \[[@CR38]\]. A number of studies have investigated the pharmacokinetics of paracetamol in healthy older adults, reporting variable effects of age \[[@CR11]\]. General health state appears to have a greater effect on paracetamol clearance than age. Although preserved in healthy older adults, clearance to paracetamol glucuronide was markedly reduced in frail elderly patients when compared with fit subjects \[[@CR39]\].

Three trials have evaluated the results of liver function tests to detect AEs with paracetamol (alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\]) in participants with OA, where an abnormal test was defined as hepatic enzyme activity 1.5 times the upper limit of normal. Participants taking paracetamol in the management of spinal pain and OA of the hip or knee were nearly four-fold more likely to have abnormal results on liver function tests than participants taking placebo (WMD 3.8, 95% CI 1.9--7.4) \[[@CR20]\].

Acute drug overdose with paracetamol may cause acute liver failure leading to transplantation (ALFT). Overdose ALFT in Europe was evaluated in the Study of Acute Liver Transplantation (SALT) \[[@CR40]\]. Overall, 600 cases of ALFT were identified in 52 transplant centres, of which paracetamol overdose, even without suicidal intent, was responsible for 20% of cases. Among 301 ALFT cases without clinical aetiology, 81 (27%) were exposed to paracetamol but without overdose in the prior 30 days. When non-overdose paracetamol-associated ALFTs were considered, the event rates were very similar, between 2.6 and 4.1 (mean 3.3) cases per million treatment-years of paracetamol sold (Table [3](#Tab3){ref-type="table"}), with no difference between countries.Table 3Non-overdose acute liver failure leading to transplantation with exposure to paracetamol within 30 days before the first symptomsCountryNon-overdose ALFTMTTYALFT/MTTY (95% CI)France4913.23.72 (2.75--4.91)Ireland10.382.63 (0.08--14.7)Italy41.412.84 (0.77--7.26)Netherlands30.734.10 (0.62--8.77)UK248.252.91 (1.86--4.33)All^a^8124.33.33 (2.65--4.14)Event rates for non-overdose paracetamol-associated ALFTs by country; mean 3.5 cases per million treatment-years of paracetamol sold. Non-overdose was defined as exposure to drugs without demonstrated overdose within 30 days prior to the index dateReproduced from Gulmez et al. \[[@CR40]\]. Copyright permission granted by John Wiley & Sons, 2019*ALFT* acute liver failure leading to registration for transplantation, *CI* confidence interval, *MTTY* million treatment-years sold^a^Includes Portugal and Greece, with no cases

Paracetamol poisoning is the major cause of severe acute hepatotoxicity in the UK. In a single-centre cohort study from the Scottish Liver Transplantation Unit, the clinical impact of staggered overdoses and delayed presentation following paracetamol overdose were examined \[[@CR41]\]. The study found that 'staggered' paracetamol overdoses (repeated supratherapeutic ingestions of paracetamol), frequently taken to relieve pain, are strongly associated with reduced survival compared with single time-point overdose \[[@CR41]\]. From the 938 cases of severe acute liver injury admitted over a period of 16 years (1992--2008), 663 (70.7%) were due to paracetamol-induced hepatotoxicity, and 161 (24.3%) had taken a 'staggered' paracetamol overdose compared with a single time-point overdose. Staggered overdose pattern was associated with older age and chronic alcohol abuse (a potential enhancer of paracetamol hepatotoxicity), resulting in worse clinical outcomes than single time-point paracetamol overdose. Relief of pain (58.2%) was the most common rationale for repeated supratherapeutic ingestion, and musculoskeletal pain was the third most common reason for staggered overdose (14.3%). Despite lower total ingested paracetamol doses and lower admission serum ALT, staggered overdose patients were more likely to be encephalopathic on admission, require renal replacement therapy or mechanical ventilation, and had higher mortality rates compared with single time-point overdoses (37.3% vs. 27.8%; *p* = 0.025). These patients are at increased risk of developing multi-organ failure.

Conclusions {#Sec12}
===========

There is a rapidly increasing OA burden in an aging and increasingly overweight/obese society. Although paracetamol is commonly used for analgesia in OA, the efficacy of paracetamol overall is poor and its use is driven by belief in its relative safety and by a lack of effective or tolerated alternative pharmacotherapies. Given that people with chronic pain may use paracetamol over many years, the only relevant safety data derives from observational studies with their attendant problems, including selection bias (participants not randomly selected) and information bias (inaccurate recording of OTC medications for example, some of which may be NSAIDs). Currently, this observational evidence suggests an increased risk of AEs with paracetamol, although the data are difficult to interpret, and paracetamol remains safer than NSAIDs. Liver function abnormalities are not uncommon with paracetamol, and accidental overdose with supratherapeutic doses of paracetamol for pain is an important issue. The true risk of paracetamol use may be higher than is currently perceived in the clinical community. In this context, while the analgesic benefit of paracetamol in OA joint pain is uncertain, more careful consideration of its use is required.
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